Abstract:The advent of biological therapy to treat many conditions, including autoimmune diseases, asthma, and even cancer, has changed the prognosis of millions of patients, decreasing morbidity and mortality and increasing quality of life. 1 1 Molinelli E, Campanati A, Ganzetti G, Offidani A. Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts. Curr Drug Saf. 2016;11(1):35-43. https://dx.doi.org/10.2174/1574886310666151014115127 https://dx.doi.org/10.2174/1574886310666... However, because of their mechanism of action, biological therapy can increase the risk of some infections, including tuberculosis. 2 2 Dobler CC. Biologic Agents and Tuberculosis. Microbiol Spectr. 2016;4(6):10.1128/microbiolspec.TNMI7-0026-2016. https://dx.doi.org/10.1128/microbiolspec.TNMI7-0026-2016 https://dx.doi.org/10.1128/microbiolspec... Latent tuberculosis infection (LTBI), or tuberculosis infection (TBI), as defined in the original article published by Sultana et al. 3 3 Sultana A, Migliori GB, D`Ambrosio L, García-García JM, Silva DR, Rendon LA, et al. Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent. J Bras Pneumol. 2024;50(4):e20240082. https://dx.doi.org/10.36416/1806-3756/e20240082 https://dx.doi.org/10.36416/1806-3756/e2... in this issue of the Journal, has a risk of reactivation increased by almost 30 times in patients using TNF-α inhibitors. 2 2 Dobler CC. Biologic Agents and Tuberculosis. Microbiol Spectr. 2016;4(6):10.1128/microbiolspec.TNMI7-0026-2016. https://dx.doi.org/10.1128/microbiolspec.TNMI7-0026-2016 https://dx.doi.org/10.1128/microbiolspec... This happens because such inhibitors block one of the most important cytokines responsible for the integrity of the tuberculous granuloma. 4 4 Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?. Clin Infect Dis. 2005;41 Suppl 3:S199-S203. https://dx.doi.org/10.1086/429998 https://dx.doi.org/10.1086/429998... However, it is still unclear whether biological therapy with other agents are associated or not with the risk of turning LTBI into active tuberculosis. 5 5 Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742-753. https://dx.doi.org/10.1136/ard-2022-223335 https://dx.doi.org/10.1136/ard-2022-2233... Additionally, clinical practice is largely heterogeneous, given different scenarios and tuberculosis burdens, which hinders the generalization of guidelines. Sultana et al. 3 3 Sultana A, Migliori GB, D`Ambrosio L, García-García JM, Silva DR, Rendon LA, et al. Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent. J Bras Pneumol. 2024;50(4):e20240082. https://dx.doi.org/10.36416/1806-3756/e20240082 https://dx.doi.org/10.36416/1806-3756/e2... bring a very interesting and timely topic by describing the different clinical practices regarding the approach to TBI worldwide and by evaluating if they are in line with their respective national or international guidelines. In that study, 3 3 Sultana A, Migliori GB, D`Ambrosio L, García-García JM, Silva DR, Rendon LA, et al. Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent. J Bras Pneumol. 2024;50(4):e20240082. https://dx.doi.org/10.36416/1806-3756/e20240082 https://dx.doi.org/10.36416/1806-3756/e2... 163 responders in 27 countries completed the survey. According to the authors, "TBI screening rates in patients treated with TNF-α inhibitors were high, especially for older TNF-α inhibitors. Most participants supported TBI screening in patients treated with B- or T-cell inhibitors but not in those treated with interleukin inhibitors. -Abstract Truncated-

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study

Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus

BI44 Latent tuberculosis reactivation in a patient with chronic plaque psoriasis treated with ustekinumab with a review of the literature

Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive Treatment

Biologic Treatment of Psoriasis and Tuberculosis Testing: A Retrospective Analysis

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents

Tuberculosis reactivation risk in dermatology

The Safety of Ustekinumab Treatment in Patients with Moderate-to-Severe Crohn's Disease and Latent Tuberculosis/HBV Infection: A Nationwide Retrospective Study

Latent tuberculosis infection and biologic agents other than TNF-α inhibitors: "over-screening and over-treatment?"

Evaluation of serial QuantiFERON-TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti-IL-17 treatment (secukinumab and ixekizumab): Real-world data from a tuberculosis-endemic country

Epidemiology of Latent Tuberculosis in Rheumatic Immune-Mediated Inflammatory Diseases—Study of 1117 Patients and Descriptive Literature Review

High Incidence of Tuberculosis Infection in Rheumatic Diseases and Impact for Chemoprophylactic Prevention of Tuberculosis Activation During Biologics Therapy

Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Is Chemoprophylaxis Necessary For All Latent Tuberculosis Infection Patients Receiving Il-17 Inhibitors? A Cohort Study

Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals

Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study

Drug Survival and Clinical Course of Patients with Cancer Treated with Biologic Therapy for Psoriasis

Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection

Use of bimekizumab to treat palmoplantar psoriasis in a patient receiving treatment for disseminated tuberculosis: A Case Report